key: cord-0989302-6kggap7k
authors: Koufakis, Theocharis; Metallidis, Symeon; Zebekakis, Pantelis; Kotsa, Kalliopi
title: Intestinal SGLT1 as a therapeutic target in COVID‐19‐related diabetes: A “two‐edged sword” hypothesis
date: 2021-03-08
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14800
sha: bbc313b0bbf30271eb6eff6e1ce997e3c2bded12
doc_id: 989302
cord_uid: 6kggap7k

Emerging data are linking coronavirus disease 2019 (COVID‐19) with an increased risk of developing new‐onset diabetes. The gut has been so far out of the frame of the discussion on the pathophysiology of COVID‐19‐induced diabetes, with the pancreas, liver, and adipose tissue being under the spotlight of medical research. Sodium‐glucose co‐transporters (SGLT) 1 represent important regulators of glucose absorption, expressed in the small intestine where they mediate almost all sodium‐dependent glucose uptake. Similar to what happens in diabetes and other viral infections, SGLT1 upregulation could result in increased intestinal glucose absorption and subsequently promote the development of hyperglycaemia in COVID‐19. Considering the above, the question whether dual SGLT (1 and 2) inhibition could contribute to improved outcomes in such cases sounds challenging, deserving further evaluation. Future studies need to clarify whether putative benefits of dual SGLT inhibition in COVID‐19 outweigh potential risks, particularly with respect to drug‐induced euglycaemic diabetic ketoacidosis, gastrointestinal side effects, and compromised host response to pathogens.

inhibition could contribute to improved outcomes in such cases sounds challenging, deserving further evaluation. Future studies need to clarify whether putative benefits of dual SGLT inhibition in COVID-19 outweigh potential risks, particularly with respect to drug-induced euglycaemic diabetic ketoacidosis, gastrointestinal side effects, and compromised host response to pathogens. antidiabetes agents and other medication were found to be at greater risk for severe COVID-19 than individuals who didn't have the above-mentioned characteristics. Obesity, a major risk factor for the development of T2D, has been also linked to poor outcomes, including severe pneumonia, intensive care unit admission, and mortality during COVID-19, probably related to increased viral entry into cells and defects in immune response. 2 COVID-19-related DKA seems to manifest peculiar-still interesting-characteristics, including the occurrence in people without a previous diagnosis of diabetes, or in those with non-insulin-dependent diabetes and adequate metabolic control prior to infection. In addition, hyperglycaemia without diabetes and new-onset diabetes have been both linked to a poorer prognosis in the context of COVID-19. 3 The development of hyperglycaemia in COVID-19, either being genuinely new or the unmasking of a previously existing occult diabetes, is the result of a pathophysiological interplay between impaired insulin secretion and action. Up to now, putative explanations for the underlying pathophysiological mechanisms through which the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce severe hyperglycaemia and subsequent DKA have mainly focused on two directions: first, a direct viral attack against beta-cells and, second, an exacerbation of insulin resistance (IR), as a result of systemic inflammation. 4 In this paper, we discuss a novel hypothesis according to which, intestinal sodium-glucose transport proteins might be implicated in the pathogenesis of COVID-19-induced diabetes and could represent a therapeutic target for the disorder in the future.

The angiotensin-converting enzyme 2 (ACE2), which is the entry point for the virus into the cells, has been shown to be expressed in the pancreatic tissue. In line with what is already known from studies conducted with other coronaviruses, it has been demonstrated that SARS-CoV-2 exerts cytotoxic effects that cause islet cell injury and impair insulin production. 5 Moreover, downregulation of ACE2 following the endocytosis of the virus complex results in increased angiotensin II concentrations, which are known to impede insulin secretion. 6, 7 Similar to what happens with other viral infections, an immune-mediated beta-cell destruction triggered by the SARS-CoV-2 infection has been also suggested. 4, 7 In a parallel way, COVID-19-related cytokine storm leading to overproduction of proinflammatory molecules, predominantly interleukin (IL)-6 and tumour necrosis factor-α (TNF-α), further aggravates beta-cell dysfunction and induces IR.

Over the past few years, the importance of the gut in the regulation of glucose homeostasis has been greatly recognized by identifying its multiple roles in modulating nutrient absorption, satiety, systemic and adipose tissue inflammation and insulin secretion and action. Although patients with COVID-19 mainly present with respiratory symptoms, a recent meta-analysis proved that approximately 12% of SARS-CoV-2-infected individuals will manifest gastrointestinal (GI) symptoms, with diarrhoea, nausea, or vomiting being the most commonly reported among them. 8 SGLT activation has recently been a key therapeutic target in T2D, where excessive glucose reabsorption by the kidneys is observed. 13 Available drugs mainly inhibit SGLT2, located in the early segment of the proximal renal tube, thus leading to reduced renal glucose reabsorption. 14 However, specific agents within the class, namely, sotagliflozin and canagliflozin, present only 20-and 250-fold higher inhibitory activity for SGLT2 compared with SGLT1, respectively, and are considered "dual inhibitors," manifesting their glucoselowering actions by reducing-apart from renal-intestinal glucose absorption, as well 15 (Table 1) . Interestingly, dual inhibition has been questionably linked to a greater risk of adverse events, including lower extremity amputations and euglycaemic DKA, compared with the more selective SGLT2 inhibitors. 14, 15 Although the exact mechanisms that could explain these differences are still debatable, they may be related to the volume depletion-mediated increased ketone body reabsorption in the distal tubules, which, in turn, could amplify the magnitude of ketonemia already observed with SGLT2 inhibition. 16 GI adverse events, such as osmotic diarrhoea, are also more common with dual inhibitors, attributable to their effects on the brush border of the small intestine. [14] [15] [16] Relevant to their remarkable cardiorenal protective properties in people with or without diabetes, previous research has highlighted the potential of SGLT2 inhibitors to decrease the concentrations of proinflammatory cytokines, reduce oxidative stress, downregulate sympathetic activity and improve cell autophagy, leading to amelioration of both systemic and adipose-tissue inflammation. 17 These seem to be class effects and not related either to SGLT1 or SGLT2 inhibition alone. In this context, dapagliflozin, a molecule with a 1200-fold higher potency for SGLT2 compared with SGLT1, is currently being tested in clinical trials as a potential treatment for acute respiratory COVID-19 disease, 17 

In conclusion, there is indirect evidence linking ACE2-mediated SGLT1 upregulation to the development of hyperglycaemia and diabetes-related adverse outcomes in COVID-19. Thus, the excessive activation of SGLT1 could be a potential therapeutic target for COVID-19-induced diabetes. The testing of the hypothesis seems to be relatively feasible, considering that dual SGLT inhibitors are already widely used in daily clinical practice for the management of T2D.

On the other hand, it should be noted that available data are still very limited. Therefore, the development of animal models for the mechanistic study of the key molecular mechanisms implicated in the SARS-CoV-2 binding receptor ACE2 mediated dysregulation of intestinal nutrient transporters is needed. 6 F I G U R E 1 Potential harms and benefits of dual SGLT (1 and 2) inhibition in COVID-19-induced diabetes. Abbreviations: ACE2, angiotensinconverting enzyme 2; COVID-19, coronavirus disease 2019; DKA, diabetic ketoacidosis; GI, gastrointestinal; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SGLT, sodium-glucose co-transporters required to investigate the potential of a tailored approach in the therapeutic management of COVID-19, but also to clarify whether putative benefits of dual SGLT inhibition outweigh potential risks, particularly with respect to drug-induced euglycaemic DKA, GI side effects, and compromised host response to pathogens.

The authors received no financial support for the research, authorship, and/or publication of this article.

Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland

Obesity and mortality of COVID-19. Meta-analysis

Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19

COVID-19 and diabetes: knowledge in progress

SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients

COVID-19 and diabetes: is there enough evidence?

Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis

Upregulation of ACE2-ANG-(1-7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport

Transmissible gastroenteritis virus infection enhances SGLT1 and GLUT2 expression to increase glucose uptake

SGLT1 deficiency turns listeria infection into a lethal disease in mice

Effects of salbutamol and phlorizin on acute pulmonary inflammation and disease severity in experimental sepsis

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab

Differentiating sodium-glucose cotransporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus

What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition

SGLT1 inhibition: pros and cons

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure due to COVID-19: the design and rationale for the DARE-19 study